Genital human papillomavirus type 68a (HPV-68a), related to the potentially oncogenic HPV-39

• US 5,981,173 A
• Filed: 02/11/1997
• Issued: 11/09/1999
• Est. Priority Date: 02/14/1996
• Status: Expired due to Term

• Current Assignee: Roche Molecular Systems (Roche Holding AG)
• Original Assignee: Institut National De La Sante Et De La Recherche Medicale (Inserm) (Allianz Global Investors GmbH), Institut Pasteur
• Inventors: Beaudenon, Sylvie, Longuet, Michele, Orth, Gerard
• Primary Examiner(s): Mosher, Mary E.
• Assistant Examiner(s): SALIMI, ALI REZA
• Application Number:
  US08/815,667
• Time in Patent Office: 1,001 Days
• Field of Search: 424/199.1, 424/204.1, 424/229.1, 536/23.72, 435/5, 435/6, 435/7.1, 435/320.1, 435/91.1
• US Class Current: 435/5
• CPC Class Codes: A61K 2039/51 comprising whole cells, viruses or DNA/RNA
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12Q 1/705 for herpetoviridae, e.g. herpes simplex, varicella zoster

Abstract

The genomes of two novel human papillomavirus (HPV) types, HPV68 and HPV70, were cloned from a low grade cervical intraepithelial neoplasia and a vulvar papilloma, respectively, and sequenced. Both types are related to HPV39, a potentially oncogenic virus. HPV68 and HPV70 were also detected in genital intraepithelial neoplasia from three patients and one patient, respectively. Comparison with sequence data in the literature indicates that the subgenomic ME180-HPV DNA fragment, cloned from a carcinoma cell line, corresponds to an HPV68 subtype and that several HPV DNA fragments amplified by PCR from genital neoplasia represent worldwide distributed variants of HPV68 and HPV70.

Claims

1. Purified human papillomavirus (HPV) 68 DNA deposited at C.N.C.M. (Collection Nationale de Culture de Microorganisms) under Accession No. I-1540.

9. A method of detecting HPV 68 in a biological sample containing nucleic acids, said method comprising contacting the nucleic acids of said biological sample with the HPV 68 DNA of either claim 1 or 2, wherein said DNA is labeled with a label selected from the group consisting of a radioactive marker and a non-radioactive marker;

detecting a hybrid between said HPV 68 DNA and said nucleic acids in the sample; and

correlating the presence of said hybrid with the presence of HPV 68 in said sample.

2. Purified human papillomavirus (HPV) 68 DNA sequence, which is selected from the group consisting of SEQ ID NO:

12 and SEQ ID NO;

13.

3. A purified HPV-68a nucleotide sequence encoding a protein, wherein said protein is selected from the group consisting of L1, L2, E6, and E7.

4. A purified HPV-68a nucleotide sequence according to claim 3, wherein said purified HPV-68a sequence, as set forth in FIG. 3A (SEQ ID NO:

6), encodes the E6 protein.

5. A purified HPV-68a nucleotide sequence according to claim 3, wherein said purified HPV-68a sequence, as set forth in FIG. 3A (SEQ ID NO:

6), encodes the E7 protein.

6. A purified HPV-68a nucleotide sequence according to claim 3, wherein said purified HPV-68a sequence, as set forth in FIG. 3B (SEQ ID NO:

9), encodes the L1 protein.

7. The nucleotide sequence of claim 3, wherein said nucleotide sequence is labeled.

8. The nucleotide sequence of claim 7, wherein said label is selected from the group consisting of a radioactive marker and a nonradioactive marker.

10. A method of detecting HPV 68 in a biological sample containing nucleic acids, said method comprising

contacting the nucleic acids of said biological sample with the nucleotide sequence of claim 7;

detecting a hybrid between said nucleotide sequence and said nucleic acids in the sample; and

correlating the presence of said hybrid with the presence of HPV 68 in said sample.

11. A process for producing cloned recombinant human papillomavirus DNA, wherein the process comprises cloning a vector in a host cell, wherein said vector comprises a human papillomavirus 68 DNA deposited at C.N.C.M. (Collection Nationale de Culture de Microorganisms) Under Accession No. I-1540.

12. The process of claim 11, wherein said vector comprises a purified human papillomavirus HPV-68a DNA sequence wherein the sequence is selected from the group consisting of SEQ ID NO:

12, and SEQ ID NO;

13.

13. The process of claim 11, wherein said vector comprises a purified human papillomavirus HPV-68a nucleotide sequence encoding a protein, wherein said protein is selected from the group consisting of L1, L2, E6, and E7.